Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Research & Development (2022 - 2025)

Stoke Therapeutics has reported Research & Development over the past 4 years, most recently at $41.7 million for Q4 2025.

  • Quarterly results put Research & Development at $41.7 million for Q4 2025, up 78.01% from a year ago — trailing twelve months through Dec 2025 was $137.9 million (up 54.74% YoY), and the annual figure for FY2025 was $137.9 million, up 54.74%.
  • Research & Development for Q4 2025 was $41.7 million at Stoke Therapeutics, up from $37.7 million in the prior quarter.
  • Over the last five years, Research & Development for STOK hit a ceiling of $41.7 million in Q4 2025 and a floor of $18.3 million in Q1 2022.
  • Median Research & Development over the past 4 years was $21.5 million (2023), compared with a mean of $24.2 million.
  • Biggest five-year swings in Research & Development: rose 0.81% in 2023 and later skyrocketed 78.01% in 2025.
  • Stoke Therapeutics' Research & Development stood at $21.1 million in 2022, then increased by 3.41% to $21.8 million in 2023, then increased by 7.55% to $23.4 million in 2024, then surged by 78.01% to $41.7 million in 2025.
  • The last three reported values for Research & Development were $41.7 million (Q4 2025), $37.7 million (Q3 2025), and $25.9 million (Q2 2025) per Business Quant data.